Day One

• Activating four distinct hormone receptors at once to provide more consistent and durable weight loss, potentially rivalling bariatric surgery, for a non-invasive alternative to a significant and lasting solution to obesity
• Balancing hormonal actions with a tetra-agonist design to mitigate the common side effects of current drugs, such as nausea and muscle loss, for improved patient tolerability and long-term adherence to therapy
• Creating a single, unimolecular compound to simplify the treatment regimen, avoiding the need for multiple drugs, for a more convenient and accessible therapeutic option for patients with complex comorbidities

• Understanding the rationale and clinical evidence for combining GLP-1 Receptor Agonists (GLP-1 RAs) with complementary agents to achieve a synergistic blockade of the complex metabolic, hemodynamic, and inflammatory pathways that drive the progression of CKD and its cardiovascular sequelae
• Recognizing how these combination strategies can be personalized for patients across the CKD spectrum, from early-stage albuminuria to advanced disease, by optimizing the balance of glucose control, weight loss, blood pressure management, and direct kidney protection to maximize the reduction in Major Adverse Kidney Events (MAKE) and associated Major Adverse Cardiovascular Events (MACE).
• Grasping the emerging role of next-generation multi-agonists (e.g., GIP/GLP-1/ Glucagon) and their combinations with non-hormonal agents in tackling the high unmet need in CKD, specifically focusing on their potential to induce substantial weight loss while providing additive renoprotective and anti inflammatory benefits superior to current dual-agent regimens

• Understanding how combining therapies like GLP-1 RAs and SGLT-2 inhibitors creates a synergistic effect that more effectively addresses the complex interplay of cardiovascular disease and comorbidities to move beyond the benefits of single-agent treatments to reduce major adverse cardiovascular events (MACE)
• Recognizing that combination therapies are proving beneficial across a wide range of patients, including those with and without diabetes, and those with varying degrees of obesity and chronic kidney disease to enable a more holistic and personalized strategy for improving cardiovascular health
• Grasping the compelling clinical evidence from recent trials demonstrating that this multi-drug approach provides significant, measurable reductions in MACE, all-cause mortality, and heart failure hospitalizations, fundamentally shifting the paradigm for high-risk cardiovascular patients

• MASH is a progressive inflammatory form of MASLD and is a leading cause of chronic liver disease worldwide
• Therapeutic strategies targeting metabolic dysfunction, inflammation and fibrosis are urgently needed
• Combination therapies and precision medicine approaches targeting these pathways will lead to histological improvement and patient reported outcomes
• Therapies targeting novel inflammatory processes may change the course of treatment of MASH

Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in GLP-1 drug development. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and therapeutic development.

• Moving beyond appetite suppression by leveraging proprietary dual-siRNA technology to target the root genetic drivers of metabolic dysfunction, promoting the ‘browning’ of white fat and significantly enhancing energy expenditure
• Preserving vital lean muscle mass while achieving selective, transformative fat loss, thereby resolving the critical body composition challenges associated with current therapies and securing healthier, more sustainable long-term metabolic outcomes
• Delivering a disruptive, patient-centric treatment option through a targeted genetic approach that offers the potential for infrequent, twice-yearly dosing, fundamentally changing the treatment paradigm and increasing diversity in the next generation of approved drugs

• Expression of GLP-1 locally within the pancreas, with low circulating GLP-1 levels, overcomes dose-limiting tolerability of pharmacologic therapy
• Local delivery of Rejuva pancreatic gene therapy avoids safety concerns of high dose systemic gene therapy
• Preclinical results support FIH study initiation in 2026

• Utilizing engineered protein translation and the incorporation of Non-Canonical Amino Acids (ncAAs) for creating new-to-nature biotherapeutics, enabling drug candidates with improved stability, efficacy, and novel mechanisms of action beyond traditional incretin agonism
• Exploring how sustainable, aqueous biomanufacturing is strategically essential to overcome the high cost and inefficiency of existing chemical synthesis methods, ensuring that next-generation peptide therapeutics can meet massive global demand
• Prioritizing platform technologies in commercialization strategy that enable rapid, cost-effective scale up and yielding differentiated products, moving the field past dose-optimization of existing drugs toward wholly novel, patient-focused treatments

• Restoring the body’s natural metabolic food response by utilizing a proprietary precision-targeted oral formulation designed for release in the distal small intestine
• Activating the endogenous release of a broad spectrum of enteric hormones like GLP-1, GLP-2, and PYY, achieving a physiological response that avoids systemic hormone over-stimulation
• Highlighting clinical trial data showing targeted glucose delivery significantly improves glucose handling and elicits competitive weight loss outcomes while maintaining a benign safety profile

• This session moves beyond treating symptoms to address the root causes of chronic illness
• We will explore the latest data on how GLP-1s are providing cardiovascular and renal protection
• Featuring case studies on approved indications and drugs in the pipeline, this session will show how GLP-1s are becoming a foundational therapy for some of the world’s most prevalent diseases

• Positive changes in the regulatory landscape of non-invasive tests, pushing the boundaries and reducing the need for invasive liver biopsies.
• The concept of High-risk MASLD
• The innovative phase 3 trial design of Lilly’s SYNERGY-Outcomes trial; mimicking clinical practice, streamline the entire development process and lower the cost of bringing a drug to approval while improving recruitment and retention

Showcase your ground-breaking research and connect with peers in a vibrant, collaborative environment. Presenting at the poster session is your chance to gain visibility and engage directly with leading experts and innovators in the GLP-1 field. This is a unique opportunity to build new relationships and strengthen existing ones. Share your latest findings, gain valuable feedback, and explore potential collaborations that will shape the next generation of GLP-1-based therapeutics. To submit a poster, please contact [email protected]

• Accelerating trial timelines with patient-friendly protocols and technology-enabled support to make it easier for participants to enrol and stay engaged throughout the study
• Providing more representative data by designing trials that are accessible to diverse patient populations to ensure the results are more broadly applicable and reflect real-world outcomes
• Building patient trust through transparent communication and a focus on participant well-being to foster a collaborative environment and increase the likelihood of long-term retention

• Integrating preclinical and clinical insights to optimize the selection of clinical endpoints, streamlining MASH drug development and accelerating the availability of effective therapies for patients
• Utilizing both preclinical data and clinical evidence to inform clinical trial design, enabling the identification of highly relevant and predictive endpoints that enhance the likelihood of demonstrating drug efficacy and achieving regulatory approval
• Employing preclinical models that accurately mirror MASH pathophysiology, along with clinical insights into disease progression and patient heterogeneity, to focus clinical trials on the most promising therapeutic targets and patient populations— thereby improving the overall success rate of MASH drug development

• Accelerating dose optimization by leveraging FNIH-validated non-invasive biomarkers (e.g., in MASH) as reliable, rapid surrogate endpoints in seamless adaptive trial models
• Defining the full therapeutic value of GLP-1s by prioritizing the early standardization and integration of multi-indication endpoints, such as muscle preservation and heart failure (HF) risk markers
• Harmonizing biomarker protocols across clinical trials and Real-World Data (RWD) to enhance patient retention and ensure robust, consistent long-term safety and efficacy analysis